Global BCMA-targeted CAR-T Cell Therapy Market 2025 by Company, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global BCMA-targeted CAR-T Cell Therapy market size was valued at US$ 1421 million in 2024 and is forecast to a readjusted size of USD 6880 million by 2031 with a CAGR of 24.4% during review period.

Chimeric antigen receptor (CAR) T-cell therapy is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer cells more effectively. Currently available CAR-T cell therapy products are divided into CD19 targets and BCMA targets. BCMA stands for B - cell maturation antigen. It is a protein that is found on the surface of plasma cells, which are abnormal cells that multiply uncontrollably in multiple myeloma, a type of blood cancer. By targeting BCMA, the CAR - T cell therapy aims to specifically attack the cancer - causing plasma cells.

Major players: The BCMA-targeted CAR-T cell therapy market presents a highly concentrated duopoly. In 2024, the global market CR2 index exceeded 98%. The main products are Carvykti (Cedacion) jointly developed by Legend Biotech and Johnson & Johnson and Abecma of Bristol-Myers Squibb. Among them, Carvykti continues to expand its market leadership with significant clinical advantages, and its global sales in 2024 increased by 93% year-on-year. In contrast, Abecma's sales in the current period decreased by about 14% year-on-year due to intensified market competition and product iteration pressure.

Market Trends: The BCMA CAR - T cell therapy market is in a phase of rapid growth. The reasons for this growth are two - fold. Firstly, there is a large population of patients with multiple myeloma, and there are many unmet medical needs. Secondly, this therapy has demonstrated good efficacy and has been recognized by the market. With the maturation of technology and market promotion, it is expected that the market will maintain a high growth rate in the coming years.

Expansion of Indications: Currently, BCMA CAR - T cell therapy is mainly used for the treatment of relapsed or refractory multiple myeloma. With the deepening of research, its indications are expected to be broadened. Pre - clinical and clinical trials are exploring its application in other hematological malignancies, such as certain types of leukemia and lymphoma. If successful, this will greatly expand the market size, bring hope to more patients, and inject new impetus into the growth of the therapy market.

Changing Competitive Landscape：The market competition is becoming increasingly fierce. In addition to the already - launched products such as Ciltacabtagene Autoleucel (Carvykti) and Idecabtagene Vicleucel (Abecma), many pharmaceutical companies are actively deploying and researching BCMA CAR - T products. New entrants may change the existing competitive landscape with innovative technologies or better cost control.

High - Cost Constraints: The research, development, and production processes of BCMA CAR - T cell therapy are complex, involving multiple high - cost links such as cell collection, gene editing, and cell culture, resulting in high product prices. This makes it difficult for many patients to afford, limiting the accessibility of the therapy and, to a certain extent, hindering the rapid expansion of the market. How to reduce costs so that more patients can benefit is an important challenge faced by the entire industry.

Safety Risks：Although this therapy has achieved remarkable results in clinical applications, there are still certain safety risks, such as cytokine release syndrome (CRS) and neurotoxicity. These adverse reactions may have a serious impact on the health of patients and even endanger their lives.

This report is a detailed and comprehensive analysis for global BCMA-targeted CAR-T Cell Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global BCMA-targeted CAR-T Cell Therapy market size and forecasts, in consumption value ($ Million), 2020-2031

Global BCMA-targeted CAR-T Cell Therapy market size and forecasts by region and country, in consumption value ($ Million), 2020-2031

Global BCMA-targeted CAR-T Cell Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031

Global BCMA-targeted CAR-T Cell Therapy market shares of main players, in revenue ($ Million), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for BCMA-targeted CAR-T Cell Therapy

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global BCMA-targeted CAR-T Cell Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Nanjing Legend Biotechnology/J&J (Carvykti), Bristol-Myers Squibb (Abecma), CARsgen, Nanjing Iaso Biotherapeutics, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

BCMA-targeted CAR-T Cell Therapy market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Abecma

Carvykti

Others

Market segment by Application

Hospital

Oncology Clinic

Market segment by players, this report covers

Nanjing Legend Biotechnology/J&J (Carvykti)

Bristol-Myers Squibb (Abecma)

CARsgen

Nanjing Iaso Biotherapeutics

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe BCMA-targeted CAR-T Cell Therapy product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of BCMA-targeted CAR-T Cell Therapy, with revenue, gross margin, and global market share of BCMA-targeted CAR-T Cell Therapy from 2020 to 2025.

Chapter 3, the BCMA-targeted CAR-T Cell Therapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and BCMA-targeted CAR-T Cell Therapy market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of BCMA-targeted CAR-T Cell Therapy.

Chapter 13, to describe BCMA-targeted CAR-T Cell Therapy research findings and conclusion.